Drug Profile
Cefiderocol - Shionogi
Alternative Names: Cefiderocol-sulfate-tosylate; FETCROJA; Fetcroja; Fetroga; FETROJA; Fetroja; GSK 2696266; RSC 649266; S-649266Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Shionogi
- Developer Shionogi; The University of Queensland
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gram-negative infections; Urinary tract infections
- Registered Nosocomial pneumonia; Ventilator associated pneumonia
- Phase II Intra-abdominal infections; Sepsis
Most Recent Events
- 14 Mar 2024 Phase-II clinical trials in Gram-negative infections (In infants, In neonates) in Taiwan, South Africa (IV) (NCT06086626)
- 14 Mar 2024 Phase-II clinical trials in Gram-negative infections (In neonates, In infants) in USA (IV) (NCT06086626)
- 31 Jan 2024 Phase-III clinical trials in Gram-negative infections in China (IV), prior to January 2024